Comparative effectiveness of glucagon-like peptide-1 agonists, dipeptidyl peptidase-4 inhibitors, and sulfonylureas on the risk of dementia in older individuals with type 2 diabetes in Sweden: an emulated trial study

EClinicalMedicine, Год журнала: 2024, Номер 73, С. 102689 - 102689

Опубликована: Июнь 20, 2024

Язык: Английский

---

Cardiovascular Benefits of GLP-1 Receptor Agonists in Patients Living with Obesity or Overweight: A Meta-analysis of Randomized Controlled Trials

American Journal of Cardiovascular Drugs, Год журнала: 2024, Номер 24(4), С. 509 - 521

Опубликована: Май 11, 2024

Язык: Английский

---

The impact of glucagon-like peptide-1 (GLP-1) agonists in the treatment of eating disorders: a systematic review and meta-analysis

Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity, Год журнала: 2025, Номер 30(1)

Опубликована: Фев. 1, 2025

Abstract Purpose Glucagon-like peptide-1 (GLP-1) receptor agonists have shown potential in managing eating disorders (EDs). Recent studies highlight their effects on pathophysiological pathways, indicating therapeutic promise, particularly for binge disorder (BED). This systematic review evaluates the of GLP-1 BED, focusing weight management and behaviors. Methods A search PubMed, Scopus, Web Science, Cochrane Library, along with manual searches, identified assessing BED patients up to November 8, 2024. Observational clinical trials meeting inclusion criteria were analyzed. Results Five (182 participants) included. Patients receiving experienced greater loss (− 3.81 kg; 95% CI − 5.14 2.49; p < 0.01, I 2 : 59.88%) compared controls. significantly reduced BMI 1.48 kg/m ) waist circumference 3.14 cm). Binge Eating Scale (BES) scores improved 8.14 points; 13.13 3.15; 0.01), though heterogeneity was noted. Conclusions underscores role management. However, given limited data, especially concerning EDs other than long-term these medications, further comprehensive are recommended evaluate impact various different across diverse demographic groups. Level evidence I, randomized controlled trials.

Язык: Английский

---

Neuropsychiatric adverse events associated with Glucagon-like peptide-1 receptor agonists: a pharmacovigilance analysis of the FDA Adverse Event Reporting System database

European Psychiatry, Год журнала: 2025, Номер 68(1)

Опубликована: Янв. 1, 2025

Abstract Background Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used due to their profound efficacy in glycemic control and weight management. Real-world observations have revealed potential neuropsychiatric adverse events (AEs) associated with GLP-1RAs. This study aimed comprehensively investigate characterize these AEs Methods We analyzed GLP-1RA reaction reports using the FDA Adverse Event Reporting System database. Disproportionality analysis reporting odds ratio (ROR) identified eight categories of conducted descriptive time-to-onset (TTO) analyses explored AE signals among individual GLP-1RAs for loss diabetes mellitus (DM) indications. Results 25,110 cases GLP-1RA-related AEs. showed an association headache (ROR 1.74, 95% confidence interval [CI] 1.65–1.84), migraine 1.28, 95%CI 1.06–1.55), olfactory sensory nerve abnormalities 2.44, 1.83–3.25; ROR 1.69, 1.54–1.85). Semaglutide a moderate suicide-related signal population 2.55, 1.97–3.31). The median TTO was 16 days (interquartile range: 3–66 days). Conclusions In this study, we and, first time, detected positive migraine, abnormalities, abnormalities. also observed semaglutide, population. provides reliable basis further investigation However, as exploratory our findings require confirmation through large-scale prospective studies.

Язык: Английский

---

Bridging metabolic syndrome and cognitive dysfunction: role of astrocytes

Frontiers in Endocrinology, Год журнала: 2024, Номер 15

Опубликована: Май 10, 2024

Metabolic syndrome (MetS) and cognitive dysfunction pose significant challenges to global health the economy. Systemic inflammation, endocrine disruption, autoregulatory impairment drive neurodegeneration microcirculatory damage in MetS. Due their unique anatomy function, astrocytes sense integrate multiple metabolic signals, including peripheral hormones nutrients. Astrocytes synapses engage a complex dialogue of energetic immunological interactions. act as bridge between MetS dysfunction, undergoing diverse activation response dysfunction. This article summarizes alterations astrocyte phenotypic characteristics across pathological factors It also discusses clinical value critical pathologic diagnostic marker potential therapeutic target for MetS-associated

Язык: Английский

---

IUPHAR review – Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target

Pharmacological Research, Год журнала: 2024, Номер 207, С. 107312 - 107312

Опубликована: Июль 18, 2024

Addiction is a chronic relapsing disease with high morbidity and mortality. Treatments for addiction include pharmacological psychosocial interventions; however, currently available medications are limited in number efficacy. The glucagon-like-peptide-1 (GLP-1) system emerging as potential novel pharmacotherapeutic target alcohol other substance use disorders (ASUDs). In this review, we summarize discuss the wealth of evidence from testing GLP-1 receptor (GLP-1R) agonist preclinical models humans ASUDs, possible mechanisms underlying impact GLP-1R agonists on alcohol/substance use, gaps knowledge, future directions. Most research has been conducted relation to use; psychostimulants, opioids, nicotine have also investigated. Preclinical suggests that reduce related outcomes. main proposed reward processing, stress, cognitive function, well broader satiety, changes gastric motility, glucose homeostasis. More in-depth mechanistic studies warranted. Clinical their findings less conclusive; most support safety efficacy ASUD treatment. Identifying preferred compounds, subgroups who responsive some key questions translate promising data into clinical settings. Several trials underway test people ASUDs.

Язык: Английский

---

Challenges, current innovations, and opportunities for managing type 2 diabetes in frail older adults: a position paper of the European Geriatric Medicine Society (EuGMS)—Special Interest Group in Diabetes

European Geriatric Medicine, Год журнала: 2025, Номер unknown

Опубликована: Фев. 27, 2025

This position paper aims to address the challenges of managing type 2 diabetes mellitus (T2DM) in frail older adults, a diverse and growing demographic with significant variability health status. The primary research questions are: How can frailty assessment be effectively integrated into care? What strategies optimize glycaemic control outcomes for adults? innovative tools technologies, including artificial intelligence (AI), improve management this population? uses 5 I's framework (Identification, Innovation, Individualization, Integration, Intelligence) integrate care, proposing such as tools, novel therapies, digital AI systems. It also examines metabolic heterogeneity, highlighting anorexic-malnourished sarcopenic-obese phenotypes. proposed highlights importance tailoring targets levels, prioritizing quality life, minimizing treatment burden. Strategies leveraging are emphasized their potential enhance personalized care. distinct needs two phenotypes outlined, specific recommendations each group. calls holistic, patient-centered approach care ensuring equity access innovations life. need fill evidence gaps, refine healthcare integration better vulnerable

Язык: Английский

---

Obesity accelerates cardiovascular ageing

European Heart Journal, Год журнала: 2025, Номер unknown

Опубликована: Апрель 8, 2025

Abstract A global obesity pandemic, coupled with an increasingly ageing population, is exacerbating the burden of cardiovascular disease. Indeed, clinical and experimental evidence underscores a potential connection between in pathogenesis various disorders. This further supported by notion that weight reduction not only effectively reduces major events elderly individuals but also considered gold standard for lifespan extension, obese non-obese model organisms. review evaluates intricate interplay from molecular mechanisms to whole organ function within system. By comparatively analysing their characteristic features, shared cell biological signatures are unveiled, intent shed light on how accelerates ageing. elaborates emerging metabolic interventions targeting might protect diseases largely through antagonizing key process itself. In sum, this aims provide valuable insight into understanding these interconnected processes could guide development novel effective therapeutics growing aged population concerning problem.

Язык: Английский

---

All GLP-1 Agonists Should, Theoretically, Cure Alzheimer’s Dementia but Dulaglutide Might Be More Effective Than the Others

Journal of Clinical Medicine, Год журнала: 2024, Номер 13(13), С. 3729 - 3729

Опубликована: Июнь 26, 2024

Addressing the dysfunctions of all brain cell types in Alzheimer's disease (AD) should cure dementia, an objective that might be achieved by GLP-1 agonist drugs, because receptors for are present main types, i.e., neurons, oligodendroglia, astroglia, microglia, endothelial cells and pericytes. This article describes benefits provided to those drugs. The uses studies humans, not rodents, describe effect agonists upon cognition, rodents' brains differ from humans so many ways results rodent may totally transferable humans. Commercially available have mostly shown either positive effects cognition or no effects. One important reason is a reduced rate entering parenchyma. Dulaglutide has greatest entry brain, at 61.8%, among agonists, seems offer best likelihood AD. Although there only one study used dulaglutide, it was randomized, placebo controlled, very large; involved 8828 participants showed significant benefit cognition. A clinical trial test hypothesis dulaglutide AD have, as its primary outcome, 30% greater than equipoise arm of, e.g., lithium plus memantine.

Язык: Английский

---

Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities

Peptides, Год журнала: 2025, Номер 187, С. 171380 - 171380

Опубликована: Март 11, 2025

Recent studies with peptide-based incretin herapies have focussed mainly on the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide and dual tirzepatide that engages receptors for GLP-1 glucose-dependent insulinotropic polypeptide (GIP). Randomised clinical trials 'real-world' confirmed marked glucose-lowering weight-lowering efficacy of these agents across diverse populations. These include different ethnic groups, young elderly individuals without diabetes and/or overweight or obesity. also protections against development progression cardiovascular renal diseases are additive to benefits conferred by improved control blood glucose body weight. Emerging evidence suggests therapies could additionally ameliorate fatty liver disease, chronic inflammation, sleep apnea possibly degenerative bone disorders cognitive decline. New incretin-based peptide in a long-acting glucagon (LY3324954), GLP-1/glucagon agonists (survodutide, pemvidutide, mazdutide, G49), triple GLP-1/GIP/glucagon (retatrutide, efocipegtrutide), combination amylin analogue cagrilintide (CagriSema), unimolecular GLP-1/amylin (amycretin), GIP antibody agonism (MariTide). The creation multi-targeting synthetic peptides provides opportunities management type 2 obesity as well new therapeutic approaches an expanding list associated co-morbidities. aim review is acquaint reader developments field from 2023 present (February 2025).

Язык: Английский

---